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Abstract
Clozapine is a particularly effective antipsychotic medication but its use is curtailed by the risk of 
clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction 
occurring in up to 1% of treated individuals. Identifying genetic risk factors for CIAG could 
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enable safer and more widespread use of clozapine. Here we perform the largest and most 
comprehensive genetic study of CIAG to date by interrogating 163 cases using genome-wide 
genotyping and whole-exome sequencing. We find that two loci in the major histocompatibility 
complex are independently associated with CIAG: a single amino acid in HLA-DQB1 (126Q) 
(P=4.7×10−14, odds ratio, OR=0.19, 95% CI 0.12–0.29) and an amino acid change in the 
extracellular binding pocket of HLA-B (158T) (P=6.4×10−10, OR=3.3, 95% CI 2.3–4.9). These 
associations dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug 
responses for other medications, and provide insight into the pathophysiology of CIAG.
Introduction
Clozapine-induced agranulocytosis/granulocytopenia (CIAG) is a rare adverse drug event 
that occurs in 1% of treated individuals and can be fatal if not detected early1. As a result, 
clozapine is underused despite its superior efficacy and particular utility in treatment-
resistant schizophrenia2. Our goal is to identify genetic risk factors for CIAG that could 
enable safer and increased use of clozapine.
Because of the specific nature of this adverse drug response and the role of the major 
histocompatibility complex (MHC) in adverse drug responses, candidate gene studies have 
focused on human leukocyte antigen (HLA) alleles in CIAG.3, 4, 5, 6, 7, 8 A small exome 
sequencing study of CIAG was unrevealing9. While nominally significant HLA associations 
have been reported, no study to our knowledge has reported unequivocal statistical 
significance or the dissection of the complex linkage disequilibrium (LD) relationships in 
the MHC.
Using multiple ascertainment schemes, we assemble the largest CIAG cohort to date (163 
cases, 54.0% never previously reported, Supplementary Table 1). We conduct a genome 
survey using whole-exome sequencing and genome-wide genotyping to test for association 
with CIAG (Figure 1, Supplementary Table 2). We show CIAG is associated with two 
independent amino acid changes in HLA-B (158T) and HLA-DQB1 (126Q). However, the 
odds ratios for these risk factors do not suggest immediate clinical application in predictive 
testing.
Results
Genome-wide common variant association study
We performed a genome-wide association study of 8,809,853 genotyped and imputed 
common variants in 161 CIAG cases (2 additional cases had exome sequencing or exome 
array data) and 1,196 controls of European ancestry. After controlling for ancestry 
(Supplementary Fig. 1), no loci exceeded genome-wide significance (P < 5×10−8, Figure 2). 
Our sample size was powered to detect common genetic variants with effect sizes of clinical 
utility (e.g., power was >99% for an odds ratio > 4 and MAF > 10%) (Supplementary Fig. 
2). The SNP with the best evidence for association was in an intron in HLA-B (rs41549217, 
P=2.07×10−7, OR=4.66, 95% CI 2.6–8.3, Supplementary Data 1). We specifically examined 
the distribution of p-values of SNPs previously shown to be associated with immune-
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mediated diseases, but did not detect any enrichment (Supplementary Fig. 3). Evaluation of 
copy number variation did not reveal any associations with CIAG. No protein encoded by a 
gene implicated by GWAS is known to bind clozapine10.
Exome-wide rare variant association study
We tested protein-coding variants (MAF < 5%) for association using whole-exome 
sequencing data from 67 CIAG cases and 376 untreated population controls. For variants 
that were also genotyped on the exome array, we merged the sequencing data with exome 
array data from 81 CIAG cases and 3,294 controls of European ancestry. We also used raw 
count data from ~4,300 samples of European ancestry from the NHLBI Exome Sequencing 
Project as an additional control reference to increase statistical power11. The top finding is a 
low frequency missense variant in BTNL2 annotated as benign by PolyPhen-2 (rs28362679, 
P=4.14×10−7, OR=3.9, 95% CI 1.2–12.9, Supplementary Data 2).
Next, we used a burden test to evaluate whether cases were more likely to be carriers of a 
functional variant in a gene compared to controls in the exome sequencing data. We divided 
rare variants into different functional categories and MAF ranges and found that BTNL2 
(P=7.0×10−8) was the only gene to exceed a conservative significance threshold of 
P=2.5×10−6, corresponding to a Bonferroni correction of 20,000 genes tested12 (Figure 3). 
None of the protein products of these genes is known to bind clozapine10. The BTNL2 signal 
is driven by two independent variants: the top SNP noted above (rs28362679) and a 
conditionally independent missense variant annotated as benign by PolyPhen-2 
(rs143211074; P=6.0×10−6, OR=4.4, 95% CI 1.10–17.8). These associations replicated 
using the exome array and NHLBI Exome Sequencing Project data (Supplementary Fig. 4). 
BTNL2 is in the MHC region and is in strong LD with HLA-DQB1 and HLA-DRB1, which 
have been associated with autoimmune diseases and adverse drug reactions including 
CIAG7, 13. BTNL2 codes for the butyrophilin-like protein 2, a member of the 
immunoglobulin gene superfamily with a role in regulating T-cell activation14. Given its 
location in a region of very high LD, the BTNL2 association could implicate it directly or 
reflect indirect associations with classical HLA alleles.
Classical HLA allele imputation
We imputed four-digit classical HLA alleles and amino acid sequences in 162 CIAG cases 
and 4,319 controls of European ancestry15 from a reference panel of 5,225 individuals using 
SNP2HLA15. The cases, mainly of northwestern European and Ashkenazi Jewish ancestry, 
were well-matched to controls (Supplementary Fig. 5). Two independent loci are associated 
with CIAG after multiple-testing correction (Figure 4). The top signal is an amino acid 
change in HLA-DQB1 (126Q) that is in strong LD with HLA-DQB1*05:02 (P=4.7×10−14, 
OR=0.19, 95% CI 0.12–0.29). After conditioning on HLA-DQB1 126Q, a genome-wide 
significant signal in HLA-B remains (threonine to alanine at residue 158, Pcond =1.54×10−8, 
OR=3.11, 95% CI 2.1–4.6). No other statistically significant loci remain after conditioning 
on both HLA-DQB1 126Q and HLA-B 158T (Supplementary Data 3).
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HLA-DQB1 and HLA-B explains the MHC signal better than BTNL2
To determine whether the BTNL2 signal is independent of the HLA-B 158T and HLA-DQB1 
126Q signals, we analyzed samples with imputed HLA alleles and genotyped BTNL2 
variants (146 CIAG cases and 3,364 controls). In conditional analyses, we observed that the 
most associated BTNL2 variant (rs28362679) was in high LD with HLA-DQB1 126Q 
(R2=0.618) and the other BTNL2 variant (rs143211074) had a low correlation with HLA-B 
158T (R2=0.042) (Supplementary Fig. 6). To determine whether the association in the 
region was better explained by the two variants in BTNL2 or the two HLA-alleles, we 
compared the likelihoods of models with HLA-DQB1 126Q and HLA-B 158T predicting 
CIAG compared to a model with the two BTNL2 variants. The combination of HLA-DQB1 
126Q and HLA-B 158T is 27,000 times more likely to explain the MHC association with 
CIAG than the two BTNL2 variants. We also looked at whether a model including one or 
both BTNL2 variants in addition to HLA-DQB1 126Q and HLA-B 158T explained the 
association better than HLA-B and HLA-DQB1 alone. We found including rs143211074 in 
the model was 13 times more likely to explain the association than the two-component 
model of HLA-B and HLA-DQB1, but there was no improvement when we added 
rs28362679. These results indicate rs143211074 could be independently associated with 
CIAG, but the more likely explanation is rs143211074 is tagging an HLA haplotype that is 
not genome-wide significant on its own (given that rs143211074 and HLA-DRB1*04:02 are 
highly correlated with R2=0.77).
HLA sequence alignment
We used the IMGT/HLA database16 (http://www.ebi.ac.uk/ipd/imgt/hla) to determine which 
classical alleles correspond to HLA-DQB1 126Q and HLA-B 158T and to align these results 
with previous candidate gene studies of CIAG. Since having a glutamine at position 126 in 
HLA-DQB1 is protective for CIAG, the most common high-risk allele is HLA-DQB1*05:02 
which has a histidine at position 126. This is consistent with prior reports of an association 
of CIAG with HLA-DQB1 6672G>C (a variant in strong LD with HLA-DQB1*05:02)4, 5. 
HLA-B*38, HLA-B*39, and HLA-B*67 are the most common alleles with a threonine at 
position 158 in the protein sequence (consistent with previous reports although none met 
contemporary significance levels)3, 4, 8. Our results cannot differentiate whether the amino 
acids we identified are causal or whether the overall configuration of these genetically 
related isoforms confers risk for CIAG.
CIAG severity by HLA-B and HLA-DQB1 carrier status
Finally, we tested for differences in CIAG severity (as indexed by minimum absolute 
neutrophil count, ANC) according to risk allele status of HLA-DQB1 and HLA-B among 149 
cases with these data. Cases who were carriers of HLA-B 158T demonstrated significantly 
lower ANC than non-carriers (P<0.01, Figure 5). However, as nearly all cases with 
substantial Ashkenazi Jewish ancestry carried the HLA-B 158T allele (Supplementary Fig. 
7), it is not possible to determine conclusively whether some of this signal could be driven 
by an unexplored feature of ascertainment or population difference. Hence we repeated the 
analysis after excluding cases with Ashkenazi Jewish ancestry (PC1>0.02) and subsequently 
correcting the phenotype for ancestry and sample cohort and observed a consistent effect but 
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of reduced significance (P=0.049) owing to reduced power because of the number of 158T 
alleles excluded (Supplementary Fig. 8). Similar analyses of time to onset of CIAG were not 
significant (data not shown).
Modeling of clozapine binding to HLA-B
The associations of HLA-DQB1 and HLA-B with CIAG are biologically plausible. HLA-
DQB1 is part of the MHC Class II antigen-presentation pathway and has been associated 
with autoimmune diseases (e.g., rheumatoid arthritis)17 and a range of immunogenetic 
phenomena (e.g., allergic sensitization, human papillomavirus seropositivity, and chronic 
hepatitis B infection)18, 19, 20. HLA-B is an important component of the MHC Class I 
antigen-presentation pathway and a “hot spot” for serious adverse drug reactions including 
flucloxacillin-induced liver injury,21 carbamazepine-induced Stevens-Johnson syndrome22, 
and abacavir hypersensitivity syndrome23. For several of these adverse drug reactions, the 
mechanism appears to be off-target binding of a drug molecule to the antigen-binding cleft 
of the HLA-B protein23.
Similar to what has been done for abacavir23, we used a molecular docking approach to 
determine that clozapine binds with relatively high affinity to the putative HLA-B*39 
antigen-presenting peptide groove when there is a threonine at position 158 (Figure 6). 
Docking simulations also suggested a potential for clozapine to bind in the pockets of HLA-
B*57:01 and HLA-B*35:08 with predicted affinities much higher than that for multiple other 
HLA-B variants (Supplementary Fig. 9). As a negative control, docking studies showed that 
clozapine had low binding affinities for the antigen-presenting pockets of HLA-A proteins.
Discussion
In conclusion, we identified two independent loci in the MHC region that are associated 
with CIAG: HLA-DQB1 and HLA-B. These findings are consistent with previous results but 
the evidence is now much stronger in this comprehensive analysis. Moreover, we localized 
the signal to two amino acids (HLA-DQB1 126Q and HLA-B 158T), but cannot distinguish 
whether these amino acids are causal or if the overall configuration of the alleles confers risk 
for CIAG. Although these data greatly clarify the contributions of HLA variation to CIAG, 
the odds ratios do not immediately suggest clinical application in screening. If we consider a 
genetic test that was positive if an individual carried either risk factor, the sensitivity and 
specificity of such a test would be 0.36 and 0.89. Because more than half of cases do not 
carry these two relatively infrequent risk factors, a predictive test based solely on HLA-
DQB1 and HLA-B could not define a truly “safe” group for clozapine use. We note that 7 
CIAG cases (4.3%) carried two risk alleles, suggesting that this combination had particularly 
high risk compared to the population expectation of 0.3–0.4%. These genetic insights could 
further understanding of the biological process underlying CIAG and, as other non-genetic 
and genetic risk factors for CIAG are identified, constitute an important component of tests 
to screen patients for the safer use of clozapine.
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Methods
Ethical Statement
The study was approved by Institutional Review Boards at the University of North Carolina 
(http://research.unc.edu/offices/human-research-ethics) and at Massachusetts General 
Hospital (http://healthcare.partners.org/phsirb). Research was carried out in accordance with 
the Declaration of Helsinki. Written informed consent was obtained from all participants (or 
legal guardians, if applicable).
Sample Description
We formed the Clozapine-Induced Agranulocytosis Consortium (CIAC) to further this effort 
by bringing together nearly all investigators in the area and to ascertain new cases. CIAG 
(clozapine-induced agranulocytosis/granulocytopenia) cases developed agranulocytosis 
(absolute neutrophil count, ANC < 500/mm3) or granulocytopenia (500 ≤ ANC ≤ 
1,000/mm3) while taking clozapine and without a known medical condition that increases 
risk for agranulocytosis (e.g., hematological disorder or autoimmune disease). There were 
98 cases with agranulocytosis (60.1%), 61 cases with granulocytopenia (37.4%), and 4 cases 
(2.5%) included on the basis of clinical judgment due to a precipitous drop in ANC to < 
1,500/mm3 while being intensively monitored. We allowed any primary psychiatric 
diagnosis (although most subjects had schizophrenia or schizoaffective disorder) and any 
reported ancestry was allowed. Heterogeneity due to ANC threshold, diagnosis, and ancestry 
was addressed analytically.
Subjects were identified in two ways. Opportunistic ascertainment was via a broad survey of 
colleagues to identify all worldwide samples in existing CIAG collections that allowed rapid 
and efficient identification of existing CIAG cases and controls exposed to clozapine 
without CIAG. This included cases from the International Severe Adverse Events 
Consortium (iSAEC,), http://www.saeconsortium.org). Systematic assessment included 
identification of additional cases from the Novartis and Teva clozapine registries (https://
www.clozarilcare.com/care, https://www.clozapineregistry.com), and the electronic 
pharmaceutical record from the Pennsylvania state hospital system. Briefly, we contacted 
the physician of record to confirm an episode of CIAG, the physician then obtained 
permission from the potential subject to release contact information, and we then contacted 
the subject to attempt recruitment into this study.
We attempted to obtain and review medical records for all subjects. Using a standardized 
review form, we abstracted demographic data, clinical diagnosis, and clozapine dosage, 
exposure duration, and the lowest ANC. Two senior CIAC clinicians evaluated all available 
data to verify CIAG case status. Most DNA samples were extracted from peripheral venous 
blood; a subset of DNA samples were from lymphoblastoid cell lines or oral sources. Most 
samples were subjected to standard quality control procedures (DNA quantification, 
electrophoresis to assess degradation, and genotyping a “fingerprint” of 25 common SNPs 
using a Sequenom iPLEX panel). Genotype data confirmed that all subjects were 
independent and of European ancestry (see below).
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A combination of clozapine-treated and untreated controls was used to increase statistical 
power. Clozapine-treated controls had received clozapine for over one year with no 
documented ANC < 1,500/mm3 and no medical condition with an increased risk of 
agranulocytosis. Ascertainment of clozapine-treated controls was performed in the same 
manner as for the cases. Untreated controls were broadly consented population controls 
ascertained in unrelated disease and cohort studies. Allele frequency data from the NHLBI 
Exome Sequencing Project (ESP) were also used.
Generation of Genome-wide Array Data
385 samples from CIAC (135 cases and 249 treated controls) were genotyped on the 
Illumina OmniExpress array at Duke University. We supplemented the CIAC data with 839 
untreated population controls from the United Kingdom Blood Service cohort who were 
genotyped on the Illumina OmniExpress platform at the Broad Institute. In addition, 26 case 
samples from the International Serious Adverse Events Consortium (iSAEC, http://
www.saeconsortium.org) were genotyped at Duke University. These data were merged with 
108 untreated population controls from the NIMH repository genotyped on Illumina arrays 
at the University of Michigan. Genotype calls were generated using Illumina’s 
GenomeStudio software. All samples had a call rate > 98% and an inbreeding coefficient 
between −0.2 and 0.2. SNPs were included if the call rate was > 98%, were in Hardy-
Weinberg equilibrium (Pcontrol > 1×10−6, Pcase > 1×10−10), and the call rate difference 
between cases and controls was < 0.02. Samples were unrelated and of European ancestry 
via multidimensional scaling24. We used SHAPEIT25, 26 and IMPUTE227 to impute 
genotypes for all SNPs using 1000 Genomes Project data as a reference panel. The 
imputation reference set was 2,186 phased haplotypes from the 1000 Genomes Project 
(August 2012, 30,069,288 variants, release “v3.macGT1”, http://mathgen.stats.ox.ac.uk/
impute/data_download_1000G_phase1_integrated.html). Imputation was done for each 
platform separately (OmniExpress, I550K) to avoid platform-based batch effects in 
imputation.
Generation of Whole-Exome Sequencing Data
We sequenced 41 CIAC cases and 26 iSAEC cases at Duke University. Exome sequence 
from CIAC cases was captured using Agilent SureSelect 50MB kits (Santa Clara, CA) and 
sequenced using Illumina HiSeq 2000 (San Diego, CA) for paired-end 100 bp reads. The 
iSAEC samples were sequenced several years earlier using Agilent SureSelect kits (Santa 
Clara, CA) and Illumina GAII for paired-end reads (San Diego, CA). For controls, we used 
data from 376 phenotypically normal controls who had been exome sequenced at the Broad 
Institute28. All raw FASTQ data were processed using the same Picard pipeline29, 30 and 
genotype calls were generated for all data jointly using the GATK Unified Genotyper tool31 
in order to avoid batch effects.
Individual genotype calls were filtered by requiring read depth ≥ 10, genotype quality score 
≥ 30, and meeting specified allelic balance criteria (based on genotype: for 0/0 0–0.3; for 0/1 
0.3–0.7; and for 1/1 0.7–1.0). All variants were required to have a GATK PASS rating, to be 
biallelic, not to have a significant difference in call rate between cohorts (P > 0.01) 
(eliminates biases due to a variant being sequenced in one cohort but not another), and not to 
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be an insertion/deletion variant. Samples were required to have a call rate > 95%, < 600 
singleton calls, and a Ti:Tv ratio between 3.1 and 3.4. The first ten principal components 
were computed using PLINK with 14,466 independent variants with a MAF > 5% and not 
located in the MHC region.
Generation of Exome Array Data
We genotyped deleterious exonic variation and a comprehensive set of MHC tag SNPs using 
the Illumina HumanExome array (v1.0, http://genome.sph.umich.edu/wiki/
Exome_Chip_Design). Initial genotyping was conducted at Duke University and genotype 
calls were made using GenomeStudio (v2010.3, genotyping module v1.8.4) using the default 
Illumina cluster file. Samples were removed for missingness > 1% (based on common SNPs 
with MAF > 5%) or genome-wide heterozygosity outside the range of 0.1–1.2% (based on 
rarer SNPs with MAF < 5%) using the original GenomeStudio calls. Cases that failed 
quality control (N=23) were re-genotyped at the Broad Institute on the Illumina 
HumanExome array (v1.1); genotype calling and quality control were the same as for the 
Duke data except that a custom cluster file and a missingness threshold > 2% were used. We 
then used zCall to recover rare genotypes.32 After removing poorly performing samples, 
individual SNPs from the Duke data were included if they had a call rate > 97% from the 
original GenomeStudio calls, a HWE p-value > 1×10−5 and a call rate > 99.5% calculated 
from the zCalls. For the Broad data, more lenient call rate thresholds were used due to the 
small number of samples (GenomeStudio calls > 75%, zCalls > 95%).
The passing exome array data were merged with population controls of European ancestry 
broadly consented for biomedical studies. These controls included samples from the NIMH 
repository (n=1,037)33, POPRES (n=703)21, the Prospective Registry in IBD Study 
(n=254)34, the 1000 Genomes Project (n=449)35, and controls ascertained for an age-related 
macular degeneration study (n=704)36. Quality control for the shared controls was similar to 
the steps for the CIAC data, except that a call rate of 99% was used36. The final dataset 
included only SNPs passing quality control in all cohorts. We removed one member of 
putative relative pairs (π̂ > 0.2) and used EIGENSOFT37 to calculate the first 10 principal 
components based on 16,621 SNPs (MAF > 5%, excluding the extended MHC region 
(chr6:25–35 mb), and following LD pruning). 213/3366 controls were ascertained for not 
having CIAG.
HLA Allele Imputation
HLA classical alleles and amino acids were imputed using BEAGLE38 for exome array data 
or IMPUTE227 for genome array data with a reference set of 5225 samples from the Type 1 
Diabetes Genetics Consortium15. The imputation accuracy using this reference panel is 
extremely high. For example, the SNP2HLA authors found the accuracy of HLA-B*38:01 
was 99.8%, HLA-B*39:01 was 99.8%, and HLA-B*39:06 was 99.9% using the same set of 
MHC tag SNPs present on the Illumina HumanExome array compared to direct genotyping 
of these variants15. We also confirmed the accuracy of imputation of HLA-DQB1*05:02 by 
SNP2HLA using existing data for 19 samples that had PCR-based sequencing of HLA-
DQB1 6672G>C, which is in strong LD with HLA-DQB1*05:027: 37/38 imputed HLA-
DQB1*05:02 calls were concordant with the PCR-based sequencing results.
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Genome-wide common variant association study
Principal components (PCs) were calculated using EigenSoft with the merged OmniExpress 
and I550K/I610K imputed datasets. SNPs used to calculate the principal components were 
independent (LD pruned) and did not include the MHC (chr6:25–35 Mb). We tested the first 
20 principal components for phenotype association (using logistic regression) and evaluated 
their impact on the genome-wide test statistics using λ, a measure of how much the observed 
distribution of P-values deviates from the expected distribution of P-values. Five principal 
components (1–4 and 12) were included in all association analyses. The first four PCs were 
selected because it is standard practice to include the first four PCs in analyses to account 
for ancestry and, of PC5–PC20, PC12 was the only PC associated with case-control status 
(P<0.05). We performed a mega-analysis between the OmniExpress data and the I550K/
I610K imputed dosage data using PLINK with principal components (described above) as 
covariates for logistic regression. SNPs with an INFO score ≥ 0.6 (metric of imputation 
quality for a SNP) and MAF ≥ 1% in controls were considered passing. We did not observe 
any batch effects due to multiple platforms or confounding due to population ancestry as 
indicated by a value of λ = 1.047 and no false positive results (Supplementary Fig. 2).
Immune-mediated SNP Enrichment
To determine whether our GWAS results show any indication of signal in loci known to be 
associated with autoimmune diseases, we randomly drew P-values from the GWAS results 
above to create an expected null distribution. In order to make this comparison more 
representative in terms of power per SNP, random draws were only taken from the subset of 
variants with MAF > 0.05 and INFO > 0.8 (6,752,294 SNPs). We drew 100 sets of 838 
SNPs and compared the distribution of p-values to those observed in a curated list of 838 
associations to immune-mediated and autoimmune disease curated from the NHGRI GWAS 
catalog. The comparison demonstrated that CIAG association to known immune-mediated 
SNPs was not distinguishable from random draws of SNPs.
Exome-wide rare variant association study
Because we had data from different platforms for rare exonic variants (exome sequencing, 
array, and allele counts from the Exome Sequencing Project11, ESP, available at http://
evs.gs.washington.edu/EVS), we used the following procedure to combine allele counts. If a 
variant was assayed on multiple platforms, we ensured the MAFs between the controls did 
not differ (P > 0.001). If the MAFs in controls were not compatible, we removed data in the 
following order: ESP, exome array, and exome sequencing. For each variant, we added 
allele counts for each technology in both cases and controls and used Fisher’s exact test on 
the combined sample to test for significance.
Variants were functionally annotated using the Variant Effect Predictor tool from 
Ensembl39. We then divided the annotations into three categories. The most restrictive 
grouping included all nonsense and splice-region variants. The intermediate grouping 
included all nonsense, splice-region, and missense variants annotated as probably damaging 
by PolyPhen-240. The least restrictive grouping included all nonsense, splice-region, 
missense, and untranslated region variants. To test for an excess burden of rare and 
functional variants, we used Fisher’s exact test where the variable of interest is the number 
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of carriers of a functional variant. We used the number of carriers of a functional variant 
instead of the total minor allele count as the testing variable to account for LD between 
variants.
MHC Association Analysis
We used imputed HLA classical alleles from all samples that were genotyped on the exome 
array. For the remaining samples that were not genotyped on the exome array, we imputed 
HLA classical alleles from either OmniExpress or I500K. Principal components were 
calculated from 6000 independent markers that were present on all three platforms to obtain 
one consistent set of principal components for all samples using PLINK (Supplementary 
Fig. 5). We merged the imputed dosage data from all three platforms to do a mega-analysis 
and used logistic regression to calculate association test statistics for each imputed allele 
using the first 10 principal components as covariates in PLINK to account for any 
confounding due to population structure. For conditional analyses, we used the dosage of the 
conditioning marker as an additional covariate in the analysis.
Model Comparison
We used R to compute the log-likelihood of a logistic regression model consisting of either 
the top two BTNL2 missense variants or HLA-DQB1 126Q and HLA-B 158T dosages with 
the first ten principal components as covariates in 144 cases and 3,355 controls. We also 
explored whether adding one or both BTNL2 variants improved the model consisting of 
HLA-DQB1 126Q and HLA-B 158T.
Linkage Disequilibrium Calculations
We used PLINK to calculate the R2 between each pair of variants in both cases and controls 
who had BTNL2 and HLA imputation data (n=146 cases and 3,364 controls). Haploview41 
was used to plot the LD between the top BTNL2 variants, HLA-B 158T, HLA-DQB1 126Q 
alleles, and the top HLA-DRB1 alleles (*04:02 and *16:01).
Wilcoxon-Rank Sum Tests
We used a Wilcoxon-Rank Sum test in R to determine whether the ANC distribution 
between carriers and non-carriers of HLA risk alleles was different in cases who had a 
lowest recorded ANC ≤ 1000 (n=149). To correct for covariates, we used the residuals of the 
regression between ANC and the principal components and cohort indicator as the 
quantitative variable for the Wilcoxon-rank sum test (Supplementary Fig. 8). For samples 
with dosage, treatment duration, and minimum ANC available (n = 92), we calculated the 
correlation between these variables. ANC is moderately correlated with treatment duration 
(R2 = 0.165) and weakly correlated with clozapine dosage (R2 = 0.035). Treatment duration 
is moderately correlated with dosage (R2 = 0.229). Carrier status was determined using the 
best guess genotype for the HLA-B 158T and HLA-DQB1 126Q alleles.
Copy Number Variation Analysis
To generate CNV genotypes, we applied PennCNV to the Illumina OmniExpress data. We 
removed any samples that had a log R ratio standard deviation > 0.3 or that were above the 
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95th percentile for the number of CNV calls leaving 134 cases and 242 controls. CNVs 
included for analysis were required to have > 10 SNP probes, > 20 kb in length, < 50% 
overlap with large genome gaps, and with MAF < 1% in controls. We used PLINK to test 
for CIAG association using the “--cnv-test-2sided” command with significance determined 
using 100,000 permutations. The family-wise corrected P-values were examined. No rare 
CNV was significantly associated with CIAG (data not shown).
Molecular Docking
We used the Maestro 2012 software suite (Schrödinger, http://www.schrodinger.com) to 
build a homology model of HLA-B39 using the protein structures of HLA-B*08 (Protein 
Data Bank, PDB, http://www.wwpdb.org, code = 3SPV, resolution 1.30Å) and HLA-B*41 
(PDB code = 3LN4, resolution 1.30 Å) as templates. We also used a multiple sequence 
alignment encompassing HLA-B*08, B41, and B38. Clozapine was docked into the antigen-
presenting site of the predicted structure of HLA-B39 using the Glide program in extra-
precision docking mode (Glide XP). Ionizable groups were first converted to their most 
probable charged forms at pH 7.4 using the LIGPREP software within Maestro. The binding 
region was defined by a 10Å × 10Å × 10Å box centered on the B39 pocket. A scaling factor 
of 0.8 was applied to the van der Waals radii. Default settings were used for all the 
remaining parameters. The docking poses were energy-minimized with Macromodel in the 
OPLS2005 force field with flexible ligand and rigid receptor. The refined poses were re-
ranked on the basis of the calculated interaction energy. The lowest-energy pose was 
selected and rescored in the active site using GlideScore XP. Clozapine was also docked in 
the antigen-presenting sites of HLA-B*57:01 (PDB code = 3VRI), HLA-B*35:08 (PDB code 
= 3BWA), and the binding pockets of other HLA-A and HLA-B proteins.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study Design
Our study design consisted of looking for genetic associations with CIAG across the minor 
allele frequency spectrum. (A) First, we recruited CIAG cases (red circle) and both treated 
and untreated controls (blue circles). Next, we used multiple technologies to genotype 
variants including genotyping arrays for both common and rare variants, whole-exome 
sequencing, imputation of classical HLA 4-digit alleles and amino acids in the major 
histocompatibility complex, and copy number variants. Lastly, we performed association 
tests for each class of variants. Results that exceeded the multiple testing threshold are 
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colored in yellow. References to figures and tables are listed in blue italics. (B) We used 
multiple technologies to genotype variants including whole-exome sequencing (green), 
exome array (pink), OmniExpress (blue) and Illumina 550K genome-wide arrays (orange). 
In addition, we used allele counts from the Exome Sequencing Project as extra control 
chromosomes (purple). As demonstrated by the Venn diagrams, the majority of cases 
(n=163) and treated controls (n=250) were genotyped on more than one platform.
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Figure 2. GWAS Manhattan Plot
We performed a genome-wide association study for 161 cases and 1196 controls. We did not 
find any loci that exceeded the threshold for genome-wide significance of 5×10−8 (red line). 
The most significant SNP is rs41549217, in an intron of HLA-B (P=2.07×10−7, logistic 
regression).
Goldstein et al. Page 17
Nat Commun. Author manuscript; available in PMC 2015 March 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Gene-Burden Test Results
We evaluated whether cases were more likely to carry rare functional variants in a gene 
compared to controls using sequencing data from 67 cases and 376 controls. Variants were 
annotated using the Variant Effect Predictor tool and divided into three sets of severity. The 
most severe category consists of loss-of-function (LOF) variants annotated as being 
nonsense and splice site (green). The intermediate category included all LOF variants as 
well as missense variants annotated as probably damaging by PolyPhen-2 (magenta). The 
least severe category consisted of all LOF, missense, and untranslated region (UTR) variants 
(blue). We had varying minor allele frequency (MAF) cutoffs with the most restrictive being 
0–1% MAF and the most inclusive being 0–5%. For each MAF and variant set, we assessed 
whether any genes deviated from expectation as demonstrated by the diagonal line. The only 
gene that showed enrichment was BTNL2 (P=7.0×10−8, Fisher’s Exact Test).
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Figure 4. Manhattan Plot of the MHC Region from HLA Imputation
This figure shows the association results of CIAG to imputed HLA classical alleles, amino 
acids, and SNPs for 161 cases and 4300 controls. (A) The top signal is from a single amino 
acid in HLA-DQB1 (126Q) (P=4.7×10−14, OR=0.19, logistic regression). All variants with 
an R2 > 0.1 with HLA-DQB1 126Q are colored green. (B) After conditioning on HLA-DQB1 
126Q as demonstrated by the green arrow, the top signal is a single amino acid in HLA-B 
(158T) (Pcond =1.54×10−8, OR=3.11, logistic regression). All variants with an R2 > 0.1 with 
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HLA-B 158T are colored purple. (C) After conditioning on HLA-DQB1 126 Q and HLA-B 
158T (purple and green arrows), no genome-wide significant loci remain.
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Figure 5. Absolute Neutrophil Count Stratified by HLA Risk Allele Carrier Status
(A) For cases in which the lowest recorded absolute neutrophil count (ANC) data were 
available, we ordered samples by the ANC and colored the points by their imputed carrier 
status of HLA-DQB1 126Q and HLA-B 158T (black=no risk alleles, red=only a carrier of 
HLA-DQB1 risk alleles as tagged by 126Q, green=only a carrier of HLA-B 158T, 
blue=carrier of both HLA-DQB1 and HLA-B risk alleles). The background colors 
demonstrate the clinical definitions for agranulocytosis (red: ANC<500) and severe 
granulocytopenia (yellow: 500≤ANC≤1000). (B) The same data are shown as a box plot to 
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demonstrate that HLA-B 158T carriers demonstrate a trend towards lower ANC than non-
carriers of HLA-B 158T.
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Figure 6. Predicted binding pose of clozapine in the antigen-presenting pocket of HLA-B* 39
Docking of clozapine into the putative antigen binding pocket of the homology model of 
HLA-B39 identified a binding pose (shown in this figure) with the highest predicted binding 
affinity. Residues in the protein binding pocket involved in specific interactions with 
clozapine are annotated.
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